drugset / Trial / NCT06792552
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
414 enrolled
NextCure, Inc.
Shanghai Xianxiang Medical Technology Co., Ltd. · collab
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
Timeline
- Start
- 2025-02-26
- Primary completion
- 2028-02
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIM0505 | Unknown | — | — |